28 Apr, 2023 Alnylam Presents 30-Month Results from ILLUMINATE-B Phase 3 Study of OXLUMO® (lumasiran) at the Pediatric Academic Societies (PAS) 2023 Meeting
New 30-month results from the ILLUMINATE-B Phase 3 study of lumasiran in pediatric patients with primary hyperoxaluria type 1 (PH1) shared at the Pediatric Academic Societies (PAS) 2023 Meeting.